Grifols acquires 40% of the capital of biotechnology firm VCN Bioscience
Grifols the world’s third largest plasma product manufacturer and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development, has acquired 40% of the equity of Catalan biotechnology firm VCN Biosciences, dedicated to the research and development of new therapeutic approaches for tumors for which there […]
Grifols acquires 40% of the capital of biotechnology firm VCN Bioscience Read More »